Research Index entry · Trial
AR1001 missed its main goal in its final-stage trial
- Evidence
- People · final-stage trial · company data
- Source
- clinicaltrials.gov
- Added
- 2 October 2026
What it is
AR1001 (mirodenafil) is a pill from the same drug family as Viagra. In AriBio’s final-stage POLARIS-AD trial of 1,535 people, it didn’t slow decline more than a placebo overall. The company points to a group the trial named in advance, the 604 people not already taking an older Alzheimer’s drug: their main memory-and-daily-life score declined 0.44 points less over a year, which AriBio calls 31 percent slower. More people quit the pill over side effects, mainly stomach trouble.
Where it stands
- Lab discovery
- Animal studies
- First studies in people
- Large trials
- Approved
The company’s own numbers, with the full data not out yet. AriBio plans to discuss them with the FDA.
Update timeline
What changed
Newest first. Only changes to the subject itself appear here: new information, or something proven wrong.
- WatchingThe Scouts look again every Friday
Only new information or a correction shows up here, not another mention of the same thing.
- Update
Research connections
Why these belong together
A connection has to say what it adds. Shared keywords alone don’t count.
Trial · Trial registry
PRI-002, a pill aimed at toxic amyloid clumps, missed its main goalThe other pill that reported at the same research meeting, in November 2026.
People · mid-stage trial